Private Equity Holding AG /
Portfolio company Enanta enters into strategic collaboration with Novartis
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. Ad hoc Press Release
Zug, February 21, 2012 Portfolio company Enanta enters into strategic collaboration with Novartis Private Equity Holding AG (PEH) is pleased to inform that portfolio company Enanta Pharmaceuticals (Enanta) has entered into a strategic collaboration with Novartis for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. PEH is a minority shareholder (<10%) and invested in Enanta in 1999 as part of the original shareholder syndicate. For more information on the strategic collaboration with Novartis and Enanta, please refer to http://www.enanta.com/pr_022112.html or http://www.enanta.com. *** Private Equity Holding AG (SIX: PEHN), managed by Alpha Associates, offers investors the opportunity to invest, within a simple legal and tax optimized structure, in a broadly diversified and professionally managed private equity portfolio. For further information, please contact: Peter Wolfers, Investor Relations, peter.wolfers@peh.ch, phone +41 41 726 79 80 or http://www.peh.ch.
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Private Equity Holding AG via Thomson Reuters ONE
HUG#1588012
|
